Affymetrix Reports Preliminary Q4 Revenues of $91M; Beats Expectations | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix today reported preliminary revenues of approximately $91 million for the fourth quarter of 2013, which would beat the consensus analyst estimate of $82.6 million.

The preliminary figure for the quarter would be an 8 percent increase over the $84.3 million the Santa Clara, Calif.-based firm posted in revenues for the fourth quarter of 2012 and includes a one-time licensing payment of $5.3 million from an unnamed diagnostic partner.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.